[go: up one dir, main page]

PE20191481A1 - Analogo de insulina novedoso y su uso - Google Patents

Analogo de insulina novedoso y su uso

Info

Publication number
PE20191481A1
PE20191481A1 PE2019001804A PE2019001804A PE20191481A1 PE 20191481 A1 PE20191481 A1 PE 20191481A1 PE 2019001804 A PE2019001804 A PE 2019001804A PE 2019001804 A PE2019001804 A PE 2019001804A PE 20191481 A1 PE20191481 A1 PE 20191481A1
Authority
PE
Peru
Prior art keywords
amino acid
chain
insulin
insulin analog
albumin
Prior art date
Application number
PE2019001804A
Other languages
English (en)
Inventor
Sang Youn Hwang
Yong Ho Huh
Jin Young Kim
Sung Hee Hong
In Young Choi
Sung Youb Jung
Se Chang Kwon
Dae Jin Kim
Hyun Uk Kim
Myung Hyun Jang
Seung Su Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20191481A1 publication Critical patent/PE20191481A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Referida a un conjugado de analogo de insulina, en el que (i) un analogo de insulina que tiene un titulo de insulina reducido en comparacion con la forma natural, en el que una cadena B o una cadena A de insulina esta modificada mediante sustitucion de un aminoacido seleccionado del grupo constituido por el 8° aminoacido, el 23° aminoacido, el 24° aminoacido, y el 25° aminoacido de cadena B y el 1° aminoacido, el 2° aminoacido, y el 19° aminoacido de cadena A con alanina; esta unido a (ii) un material biocompatible seleccionado del grupo constituido por polietilenglicol, acido graso, colesterol, albumina y sus fragmentos, materiales de union a la albumina, polimeros de unidades de repeticion de la secuencia de aminoacidos particular, anticuerpos, fragmentos de anticuerpos, materiales de union a FcRn, tejido conectivo in vivo o sus derivados, nucleotidos, fibronectina, transferrina, sacaridos, y polimeros como portador capaz de prolongar la vida media in vivo del analogo de insulina. Asimismo, revela un metodo para preparar dicho conjugado
PE2019001804A 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso PE20191481A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20130020703 2013-02-26
KR20130082511 2013-07-12
KR20140006937 2014-01-20
PCT/KR2014/001593 WO2014133324A1 (ko) 2013-02-26 2014-02-26 신규한 인슐린 아날로그 및 이의 용도

Publications (1)

Publication Number Publication Date
PE20191481A1 true PE20191481A1 (es) 2019-10-18

Family

ID=51428522

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001747A PE20151409A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso
PE2019001804A PE20191481A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001747A PE20151409A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso

Country Status (24)

Country Link
US (2) US20160008483A1 (es)
EP (2) EP2963056B1 (es)
JP (3) JP6552968B2 (es)
KR (2) KR20140106452A (es)
CN (2) CN104995206B (es)
AU (2) AU2014221531B2 (es)
BR (1) BR112015019985A2 (es)
CA (1) CA2901873C (es)
CL (1) CL2015002330A1 (es)
DK (1) DK2963056T3 (es)
ES (2) ES2868351T3 (es)
IL (1) IL240717B (es)
MX (2) MX377294B (es)
MY (1) MY186990A (es)
PE (2) PE20151409A1 (es)
PH (1) PH12015501814A1 (es)
PT (1) PT2963056T (es)
RU (1) RU2676729C2 (es)
SA (2) SA515360933B1 (es)
SG (2) SG10201907106VA (es)
TW (3) TWI755579B (es)
UA (1) UA119533C2 (es)
WO (1) WO2014133324A1 (es)
ZA (1) ZA201507104B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN104995206B (zh) * 2013-02-26 2022-04-12 韩美药品株式会社 新颖的胰岛素类似物及其用途
CR20160376A (es) * 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
WO2016133372A2 (ko) * 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
JP6987741B2 (ja) 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TW201726702A (zh) * 2015-09-24 2017-08-01 韓美藥品股份有限公司 生產胰島素之方法
KR102698929B1 (ko) * 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
US11359001B2 (en) 2016-12-09 2022-06-14 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
US20200230250A1 (en) 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
WO2018147641A1 (ko) 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
AR111341A1 (es) * 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
KR102612576B1 (ko) 2017-09-29 2023-12-12 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
JP2020535199A (ja) * 2017-09-29 2020-12-03 ハンミ ファーマシューティカル カンパニー リミテッド 効力が向上した持続性タンパク質結合体
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2020120479A1 (en) 2018-12-11 2020-06-18 Sanofi Peptide binder
CN113453703A (zh) 2018-12-21 2021-09-28 韩美药品株式会社 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
JP2022514835A (ja) 2018-12-21 2022-02-16 ハンミ ファーマシューティカル カンパニー リミテッド インスリン及びグルカゴンを含む薬学組成物
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
FI4073098T3 (fi) * 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN115427437B (zh) 2020-03-31 2024-04-19 韩美药品株式会社 新型免疫刺激il-2类似物
WO2021207599A1 (en) 2020-04-10 2021-10-14 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN113968911B (zh) * 2020-07-24 2023-10-10 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
US20250075423A1 (en) * 2021-08-02 2025-03-06 Spiber Inc. Artificial leather and method for producing same
CN117881691A (zh) * 2021-08-02 2024-04-12 丝芭博株式会社 多孔质体及其制造方法
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101743252A (zh) * 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
EP2376520B1 (en) * 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
US20120184488A1 (en) * 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
CA2806399A1 (en) * 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
KR101830344B1 (ko) * 2010-10-26 2018-02-22 한미사이언스 주식회사 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN104995206B (zh) * 2013-02-26 2022-04-12 韩美药品株式会社 新颖的胰岛素类似物及其用途

Also Published As

Publication number Publication date
CN114989289B (zh) 2024-10-01
AU2018267648B2 (en) 2020-04-16
EP2963056A4 (en) 2017-06-07
HK1211944A1 (en) 2016-06-03
EP3616727A1 (en) 2020-03-04
TW201920243A (zh) 2019-06-01
CL2015002330A1 (es) 2015-12-28
JP2016510003A (ja) 2016-04-04
JP2019187440A (ja) 2019-10-31
CA2901873A1 (en) 2014-09-04
NZ710882A (en) 2021-01-29
KR20140106452A (ko) 2014-09-03
US20180256731A1 (en) 2018-09-13
PH12015501814B1 (en) 2015-12-07
MX377294B (es) 2025-03-07
KR102413691B1 (ko) 2022-06-28
MY186990A (en) 2021-08-26
BR112015019985A2 (pt) 2017-08-29
AU2014221531A1 (en) 2015-08-27
UA119533C2 (uk) 2019-07-10
JP6552968B2 (ja) 2019-07-31
EP2963056A1 (en) 2016-01-06
WO2014133324A1 (ko) 2014-09-04
SA518400491B1 (ar) 2022-04-07
TWI708782B (zh) 2020-11-01
ZA201507104B (en) 2019-04-24
ES2868351T3 (es) 2021-10-21
SA515360933B1 (ar) 2018-12-23
SG10201907106VA (en) 2019-09-27
EP3616727B1 (en) 2021-03-31
SG11201506095TA (en) 2015-09-29
CN114989289A (zh) 2022-09-02
AU2018267648A1 (en) 2018-12-13
AU2014221531B2 (en) 2018-08-23
US20160008483A1 (en) 2016-01-14
ES2770776T3 (es) 2020-07-03
MX2015010471A (es) 2016-04-25
TW201520224A (zh) 2015-06-01
PT2963056T (pt) 2020-02-19
MX366400B (es) 2019-07-08
DK2963056T3 (da) 2020-02-17
CA2901873C (en) 2022-05-03
TWI755579B (zh) 2022-02-21
KR20210109491A (ko) 2021-09-06
IL240717A0 (en) 2015-10-29
TW201817741A (zh) 2018-05-16
IL240717B (en) 2020-05-31
PE20151409A1 (es) 2015-10-07
RU2015138536A (ru) 2017-04-03
NZ751062A (en) 2021-04-30
CN104995206A (zh) 2015-10-21
CN104995206B (zh) 2022-04-12
PH12015501814A1 (en) 2015-12-07
EP2963056B1 (en) 2019-11-13
TWI621626B (zh) 2018-04-21
RU2676729C2 (ru) 2019-01-10
JP2021193089A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
PE20191481A1 (es) Analogo de insulina novedoso y su uso
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
Quast et al. Cotranslational incorporation of non-standard amino acids using cell-free protein synthesis
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2016007722A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX389823B (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
CU20200089A7 (es) Moléculas de unión contra bcma
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
AR079551A1 (es) Anticuerpos anti-her3 y usos de los mismos
BR112018014585A2 (pt) receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
BR112014014591A8 (pt) processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
MX343640B (es) Promotor de osteogenesis.
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
CO6650338A2 (es) Antígenos de tuberculosis modificados
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CL2015001322A1 (es) Sistemas y métodos de cartílago triturado.
AR066395A1 (es) Reovirus que tienen secuencias modificadas
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método